Medikit Co.,Ltd.
Medikit Co.,Ltd. Fundamental Analysis
Medikit Co.,Ltd. (7749.T) shows moderate financial fundamentals with a PE ratio of 13.97, profit margin of 13.07%, and ROE of 6.83%. The company generates $23.6B in annual revenue with moderate year-over-year growth of 3.22%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.8/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 7749.T's fundamental strength across five key dimensions:
Efficiency Score
Weak7749.T struggles to generate sufficient returns from assets.
Valuation Score
Moderate7749.T shows balanced valuation metrics.
Growth Score
Weak7749.T faces weak or negative growth trends.
Financial Health Score
Excellent7749.T maintains a strong and stable balance sheet.
Profitability Score
Weak7749.T struggles to sustain strong margins.
Key Financial Metrics
Is 7749.T Expensive or Cheap?
P/E Ratio
7749.T trades at 13.97 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 7749.T's PEG of 24.34 indicates potential overvaluation.
Price to Book
The market values Medikit Co.,Ltd. at 0.95 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 9.64 times EBITDA. This is generally considered low.
How Well Does 7749.T Make Money?
Net Profit Margin
For every $100 in sales, Medikit Co.,Ltd. keeps $13.07 as profit after all expenses.
Operating Margin
Core operations generate 19.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.83 in profit for every $100 of shareholder equity.
ROA
Medikit Co.,Ltd. generates $5.96 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Medikit Co.,Ltd. generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
Medikit Co.,Ltd. generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
7749.T converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
13.97
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
24.34
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.95
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.82
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
6.32
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How 7749.T Stacks Against Its Sector Peers
| Metric | 7749.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 13.97 | 28.25 | Better (Cheaper) |
| ROE | 6.83% | 780.00% | Weak |
| Net Margin | 13.07% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 6.32 | 4.66 | Strong Liquidity |
| ROA | 5.96% | -14687.00% (disorted) | Weak |
7749.T outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Medikit Co.,Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
30.48%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
20.09%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
15.82%
Industry Style: Defensive, Growth, Innovation
High Growth